Bank of New York Mellon
PRME icon

Bank of New York Mellon’s Prime Medicine PRME Stock Holding History

Bank of New York Mellon’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$909K Sell
246,344
-20,875
-8% -$69.3K ﹤0.01% 3424
2026
Q1 		$930K Buy
267,219
+20,449
+8% +$77.8K ﹤0.01% 3250
2025
Q4 		$856K Buy
246,770
+49,041
+25% +$218K ﹤0.01% 3327
2025
Q3 		$1.1M Buy
197,729
+35,677
+22% +$145K ﹤0.01% 3163
2025
Q2 		$400K Buy
162,052
+6,060
+4% +$9.34K ﹤0.01% 3630
2025
Q1 		$310K Buy
155,992
+26,478
+20% +$67.5K ﹤0.01% 3689
2024
Q4 		$378K Sell
129,514
-200
-0.2% -$702 ﹤0.01% 3665
2024
Q3 		$502K Sell
129,714
-40,849
-24% -$189K ﹤0.01% 3513
2024
Q2 		$877K Buy
170,563
+64,600
+61% +$392K ﹤0.01% 3279
2024
Q1 		$742K Sell
105,963
-8,283
-7% -$62.8K ﹤0.01% 3309
2023
Q4 		$1.01M Sell
114,246
-1,143
-1% -$8.81K ﹤0.01% 3180
2023
Q3 		$1.1M Buy
115,389
+12,176
+12% +$158K ﹤0.01% 3099
2023
Q2 		$1.51M Buy
103,213
+73,145
+243% +$1.02M ﹤0.01% 2986
2023
Q1 		$370K Buy
30,068
+1,052
+4% +$17.1K ﹤0.01% 3650
2022
Q4 		$539K Buy
+29,016
New +$524K ﹤0.01% 3504

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Bank of New York Mellon's PRME Position: Q2 2026 in Review

Bank of New York Mellon reduced its Prime Medicine (PRME) stake by 7.8% in Q2 2026, selling an estimated $69.3K and leaving 246,344 shares worth $909K. The position accounts for ﹤0.01% of the portfolio, ranked #3424.

Bank of New York Mellon first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.51M in Q2 2023. 63 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Bank of New York Mellon held 246,344 shares of Prime Medicine worth $909K as of Q2 2026.
  • Bank of New York Mellon sold 20,875 Prime Medicine shares in Q2 2026, an estimated $69.3K.
  • Prime Medicine made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3424 holding.
  • Bank of New York Mellon first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Bank of New York Mellon's Prime Medicine position peaked at $1.51M in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.